Training Grant in Clinical Pharmacology

摘要 该提案代表了继续资助NIH申办的临床药理学研究的请求。 马约诊所的T32奖学金培训计划。该计划的基础是在以下方面的强有力的培训 最先进的生物医学研究应用于人类药物相互作用。马约临床药理学 培训经验包括一个课程，系统地暴露受训者的关键方面， 临床药理学的基础科学。然而，在正式课程之外， 培训是在支持性指导环境中的杰出个人研究经验。 临床药理学是一个“桥梁学科”，致力于研究药物之间的相互作用， 生物系统。然而，在生物医学领域正在发生的"革命"的背景下， 科学，一场革命，承诺改变医疗实践，临床药理学在于 融合了分子药理学、基因组学和其他"组学"学科。此外，本发明还提供了一种方法， 生物信息学、系统药理学和新的计算方法也越来越多地 成为临床药理学的关键组成部分-最终目标是真正的"个性化" 合理的药物治疗。具体而言，临床药理学旨在提高我们对 药物反应的分子基础以及在翻译界面上应用这些信息， 有可能根据潜在的疾病过程和每种疾病的独特特征来定制药物治疗， 个别患者。我们有能力利用这些巨大进步所代表的机会， 生物医学科学中正在发生的事情，以实现“最终目标”，将需要我们培养一个新的 在“系统临床药理学”中产生临床药理学家。大，全面， 像马约诊所这样的综合学术医疗中心是培养新一代 临床药理学家。马约能够做到这一点，是因为它有着悠久的支持和表演历史 突出基础和临床医学研究，并将两者结合起来。马约也有着悠久的传统， 对临床药理学学科的持续贡献以及数十年的临床药理学经验， 成功招募和培训医生科学家和实验室转化科学家， 临床药理学。在下一个供资周期，马约临床药理学奖学金培训 该计划将继续强调以支持性指导为基础的强有力的实验室研究培训 环境加入了强大的和不断发展的curriuculum和系统暴露于新的发展， 临床科学，重点是生物医学科学的快速发展的性质-所有针对 目标是使每个参加该计划的研究员成为临床领域的未来领导者。 药理学。

ABSTRACT This proposal represents a request for continued funding of the NIH-sponsored Clinical Pharmacology T32 Fellowship Training Program at the Mayo Clinic. The foundation for this program is strong training in state-of-the-art biomedical research as applied to human-drug interactions. The Mayo Clinical Pharmacology training experience includes a curriculum that systematically exposes Trainees to critical aspects of the science that underlies Clinical Pharmacology. However, beyond the formal curriculum, at the heart of the training is an outstanding individual research experience within a supportive mentoring environment. Clinical Pharmacology is a “bridge discipline” devoted to studies of the interaction between drugs and biological systems. However, within the context of the ongoing “revolution” that is occurring in biomedical science, a revolution that promises to transform medical practice, Clinical Pharmacology lies at the confluence of molecular pharmacology, genomics and other “omics” disciplines. In addition, increasingly, bioinformatics, systems pharmacology and novel computational methods are also becoming critical compotents of Clinical Pharmacology—with an ultimate goal of truly “individualized” and rational drug therapy. Specifically, Clinical Pharmacology seeks to enhance our understanding of the molecular basis for drug response and the application of that information at the translational interface to make it possible to tailor drug therapy to both the underlying disease process and the unique characteristics of each individual patient. Our ability to take advantage of the opportunity represented by the dramatic advances that are occurring in biomedical science to achieve that “ultimate goal” will require that we train a new generation of Clinical Pharmacologists in “Systems Clinical Pharmacology”. Large, comprehensive, integrated academic medical centers like the Mayo Clinic are ideally positioned to train this new generation of Clinical Pharmacologists. Mayo is able to do that because of its long history of supporting and performing outstanding basic and clinical medical research and of integrating the two. Mayo also has a long tradition of contining contributions to the discipline of Clinical Pharmacology as well as decades of experience in successfully recruiting and training both physician scientists and laboratory-based translational scientists in Clinical Pharmacology. During the next funding cycle, the Mayo Clinical Pharmacology Fellowship Training Program will continue to emphasize strong laboratory-based research training in a supportive mentored environment joined with a strong and evolving curriuculum and systematic exposure to novel developments in clinical science, with an emphasis on the rapidly advancing nature of biomedical science—all directed toward the goal of preparing each Fellow enrolled in the Program to become a future leader in Clinical Pharmacology.